- Home
- Technology
- Services
- mRNA Display-based Antibody Discovery
- mRNA Display-based Peptide Discovery
- mRNA Display-based Protein Discovery
- Applications
- About
From basic molecular and cell biology to drug discovery and diagnosis, rapid preparation of antibodies with high affinity and specificity is required in all fields. In addition to classical hybridoma technology, in vitro antibody display technology is a powerful method for screening antibodies from recombinant antibody libraries. CD BioSciences has been committed to the research of antibody field for many years, accumulated rich experience in antibody discovery, and can provide customers with multi type antibody screening services based on mRNA display technology.
Antibodies can be separated from recombinant antibody libraries in the laboratory, using a selection platform that essentially simulates in vivo processes. Many of these selection platforms have four key steps in the process of antibody generation in vivo immune system: first, the generation (or cloning) of genotype diversity; Second, the coupling of genotype and phenotype; Third, select the application of pressure; Fourth, amplification. This process first leads to a diverse set of recombinant antibody genes, and then cloning the gene set to provide a physical link between the phenotype (antigen binding behavior) of each antibody and the coding genotype. Unlike direct screening of clones for antigen binding, antibody libraries are enriched through multiple rounds of selection using target antigens and amplification, and antigen reactivity screening is performed on individual clones after several rounds.
Fig. 1 Schematic representation of the PURE mRNA display. (Nagumo, et al., 2016)
As the most developed in vitro screening technology, mRNA display relies on ternary complexes as a whole for selection. In mRNA display, there is a covalent bond between the antibody and mRNA, which is established by purinomycin as a linker. This display method is carried out completely in vitro, thus eliminating the need for cell transformation. Another advantage is that it is very easy to mutate to provide additional diversity between generations (for example, through non repetitive polymerase) without the need to convert the cloned library into E. coli.
mRNA display is a method of forming covalent linkage between cell-free synthetic protein (phenotype) and its encoding mRNA (genotype) through purinomycin, which is used to select proteins in vitro. mRNA display technology can be used to build antibody libraries up to 1014 capacity for screening multiple targets and antigens. CD BioSciences has built an antibody discovery platform based on mRNA display technology to provide customers around the world with screening services for various types of antibodies and antibody fragments to meet research needs. Our screening services include but are not limited to:
CD BioSciences has many years of project development experience in antibody discovery. Based on the mRNA display technology platform, it can provide customers with various types of antibody screening services. If you are interested in our services, please contact us for more details.
References
